Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 8, 2026, 4:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–20 of 20 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) Clear all

Conditions: Diabetes Mellitus, Type 2
Interventions: Insulin icodec, Insulin Glargine; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 205 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 12
States / cities: Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more

Conditions: Gout and Hyperuricemia
Interventions: Empagliflozin 10 mg, Placebo; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 80 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Type 1 Diabetes Mellitus, Glucokinase-Maturity Onset Diabetes of the Young (GCK-MODY), MODY2 Diabetes, Healthy Volunteer
Interventions: Study Visit 1, Placebo, Study Visit 2, Sodium Glucose Co-transporter 2 (SGLT2) Inhibitor; Procedure · Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Chronic Kidney Disease
Interventions: Lorundrostat 25mg+SGLT2i QD, Washout, Placebo+SGLT2i QD, Placebo QD + SGLT2i QD, Washout, Lorundrostat 25mg+SGLT2i QD; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 44
States / cities: Glendale, Arizona • Phoenix, Arizona • Chula Vista, California + 39 more

Conditions: Type 2 Diabetes, Diabetic Kidney Disease
Interventions: SGLT2 inhibitor; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Chronic Kidney Disease, Type 2 Diabetes Mellitus
Interventions: Finerenone (Kerendia, BAY 948862), Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Steroidal mineral corticoid receptor antagonists (sMRA), Non-steroidal mineral corticoid receptor antagonists (nsMRA); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 50,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Eden Prairie, Minnesota

Conditions: Chronic Kidney Diseases, Pediatric Kidney Disease
Interventions: Empagliflozin 10 MG; Drug
Lead sponsor: Ann & Robert H Lurie Children's Hospital of Chicago; Other
Eligibility: 12 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone (Kerendia, BAY94-8862), Sodium-glucose cotransporter-2 inhibitors (SGLT2i); Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 17,847 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Whippany, New Jersey

Conditions: Type 2 Diabetes Mellitus, Cardiovascular Diseases
Interventions: SU, DPP4, SGLT2i, GLP-1RA, SGLT2i or GLP-1RA, Linagliptin (DPP4), Exenatide (GLP-1RA), Liraglutide (GLP-1RA), Empagliflozin (SGLT2i), Glimepiride (SU), Glipizide (SU), Glimepiride (SU) or Glipizide (SU), SU or DPP4 (excluding saxagliptin and alogliptin), Exenatide (GLP-1RA) or Liraglutide (GLP-1RA); Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 18 Years to 85 Years
Enrollment: 241,981 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 6
States / cities: Pasadena, California • Pleasanton, California • Honolulu, Hawaii + 3 more

Conditions: IgA Nephropathy, Immunoglobulin A Nephropathy
Interventions: Atrasentan, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 6
States / cities: Birmingham, Alabama • Atlanta, Georgia • Oak Brook, Illinois + 3 more

Conditions: Type 2 Diabetes, Cardiac Disease
Interventions: Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 386,301 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Duchenne Muscular Dystrophy (DMD)
Interventions: SGLT-2 inhibitor, SGLT2 inhibitor; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 8 Years to 18 Years · Male only
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Peripartum Cardiomyopathy, Postpartum
Interventions: Bromocriptine, Placebo, Guideline Directed Medical Therapy for Heart Failure (GDMT), Rivaroxaban, Second Placebo; Drug
Lead sponsor: Dennis M. McNamara, MD, MS; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 64
States / cities: Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 51 more

Conditions: Type2Diabetes, ASCVD
Interventions: SGLT2 inhibitor, GLP-1 receptor agonist; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 40 Years to 80 Years
Enrollment: 6,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 36
States / cities: Huntsville, Alabama • Scottsdale, Arizona • Los Angeles, California + 31 more

Conditions: Genetic Polymorphisms, Heart Failure
Interventions: SGLT2 inhibitors (Dapagliflozin and Empagliflozin); Drug
Lead sponsor: October 6 University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 282 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Transthyretin Amyloid Cardiomyopathy
Interventions: Empagliflozin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: New York, New York

Conditions: Pediatric Brain Tumor, Pediatric Solid Tumor
Interventions: Dapagliflozin, Carmustine, Topotecan, Cyclophosphamide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 6 Years to 21 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Adult Congenital Heart Disease, Congenital Heart Disease, Systemic Right Ventricle, Transposition of the Great Arteries, Congenitally Corrected Transposition of the Great Arteries, Fontan, Single Ventricle, Tetralogy of Fallot (TOF)
Interventions: SGLT2 inhibitors; Drug
Lead sponsor: Leiden University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 3
States / cities: Baltimore, Maryland • Grand Rapids, Michigan • New York, New York

Conditions: Heart Failure, Heart Failure With Reduced Ejection Fraction
Interventions: Multiprong CDS with referral to pharmacist co-management, Multiprong CDS with GDMT order set, Focused education; Behavioral
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 4,306 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Diabetic Nephropathies, Kidney Diseases, Renal Insufficiency, Chronic, Diabetes Mellitus, Type 2
Interventions: Sodium-glucose cotransporter 2 inhibitors (SGLT2i), Renin-angiotensin-aldosterone system blockade, Glucagon-like peptide-1 receptor agonists (GLP 1 RA), Mineralocorticoid Receptor Antagonists(MRAs); Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Search by objective public record fields.

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Cardiometabolic Benefit of Reducing Iatrogenic Hyperinsulinemia Using Insulin Adjunctive Therapy in Type 1 Diabetes

Efficacy and Safety of Lorundrostat in Addition to Sodium-Glucose Cotransporter-2 Inhibitors (SGLT2i) in Subjects With Hypertension and Chronic Kidney Disease (CKD) With Albuminuria

Mechanism of SGLT2 Inhibition in the Kidney

An Observational Study, Called FINEGUST, to Learn More About How People With Chronic Kidney Disease and Type 2 Diabetes Are Treated and How the Introduction of New Treatment Options, Like Finerenone, Impacts Clinical Practice

Feasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease

An Observational Study Called FLAMINgO to Learn More About the Treatment Combination of Finerenone and SGLT2 Inhibitors in People With Long-term Kidney Disease (Chronic Kidney Disease) Together With Type 2 Diabetes by Using Routine Medical Care Data and Past Clinical Study Results

Comparison of Type 2 Diabetes Pharmacotherapy Regimens

Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy

Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy

PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

Effect of Genetic Polymorphisms on the Clinical Response to SGLT2 Inhibitors in Heart Failure Patients

SGLT2 Inhibitors in Transthyretin Amyloid Cardiomyopathy

Targeting Pediatric Brain Tumors and Relapsed/Refractory Solid Tumors With Sodium Glucose Cotransporter 2 Inhibitors (SGLT2i)

Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry

Evaluating Strategies to Improve Guideline Directed Medical Therapy: The GDMT Research, Education & Assist Trial for Heart Failure Care

Transformative Research in Diabetic Nephropathy 2.0